Case Report

Topical Imiquimod for the Treatment of Relapsed Cutaneous Langerhans Cell Histiocytosis after Chemotherapy in an Elderly Patient

Shinsaku Imashuku,1 Miyako Kobayashi,2 Yoichi Nishii,3 and Keisuke Nishimura4

1Department of Laboratory Medicine, Uji-Tokushukai Medical Center, Uji 611-0042, Japan
2Department of Internal Medicine, Uji-Tokushukai Medical Center, Uji 611-0042, Japan
3Division of Plastic Surgery, Uji-Tokushukai Medical Center, Uji 611-0042, Japan
4Department of Pathology, Uji-Tokushukai Medical Center, Uji 611-0042, Japan

Correspondence should be addressed to Shinsaku Imashuku; shinim95@mbox.kyoto-inet.or.jp

Received 12 August 2017; Revised 1 November 2017; Accepted 13 November 2017; Published 3 January 2018

Academic Editor: Ioannis D. Bassukas

Copyright © 2018 Shinsaku Imashuku et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Diagnosis and treatment of Langerhans cell histiocytosis (LCH) in elderly patients are often difficult. We report here a 61-year-old female suffering from a refractory axillary ulcer for nearly a year, whose biopsy revealed LCH. It was also noted that the patient had other cutaneous papulovesicular eruptions of LCH as well as central diabetes insipidus. The patient was first successfully treated with multiagent chemotherapy (cytosine arabinoside/vinblastine/prednisolone). DDAVP also well controlled diabetes insipidus; however, the axillary ulcer and cutaneous LCH relapsed. Thereafter, we found topical imiquimod to be effective in the treatment of relapsed cutaneous LCH lesions.

1. Introduction

Langerhans cell histiocytosis (LCH) is a rare disease characterized by granulomatous lesions consisting of clonal CD1a+/CD207+/S100+ immature dendritic cells and various inflammatory cells. Currently, LCH is defined as inflammatory myeloid neoplasia [1]. Approximately two-thirds of LCH cases occur in pediatric patients, while the remaining one-third occur in adult patients. In an analysis of 275 adults with LCH, involvement of the lungs was the highest (58.4%), followed by bone (57.3%), skin (36.9%), and central diabetes insipidus (29.6%) [2]. However, LCH in adults is often misdiagnosed because of its rarity, particularly cutaneous lesions, which affect the scalp, neck, axilla, groin, and trunk with various forms from papules to vesicles; thus, if not biopsied, cutaneous LCH is overlooked as nonspecific eruptions. In terms of treatment of LCH, multiagent chemotherapy is employed for systemic multifocal lesions [3, 4]. On the other hand, for isolated cutaneous LCH, oral or topical steroids are considered as first-line treatment [5]; however, the appropriate therapy for refractory cutaneous LCH cases remains controversial. To date, various therapies such as topical nitrogen mustard [6] or thalidomide [7] and systemic low-dose methotrexate [8] or interferon- (IFN-) alpha [9] were reported. In addition, although numbers are limited, the effectiveness of topical imiquimod treatment was described [10–13]. Here, we report on an elderly patient whose relapsed, postchemotherapy cutaneous LCH lesions were successfully treated with topical imiquimod.

2. Case Report

The case described here is a 61-year-old Japanese female who had been treated for diabetes mellitus and a refractory large ulcer (2.0 cm × 2.6 cm) at her right axilla (Figure 1(a)) for nearly a year. Eventually, the ulcer was biopsied, revealing a typical LCH pathology, with dermal infiltrate of morphologically characteristic Langerhans cells extending into the epidermis, which were positive for S100, CD1a, and CD207, with other inflammatory cells (Figure 2). Prior to
the diagnosis, cutaneous eruptions, such as erythematous papules/vesicles at retroauricular regions, crusted papules at the scalp, and reddish-brown papules at the lower chest under the breasts, were present (Figures 1(b), 1(c), and 1(d)). These cutaneous lesions remained undiagnosed until a biopsy of the retroauricular papule was performed which also revealed an LCH pathology. It was thought that one of such cutaneous eruptions caused a deep ulcer in the axillary. Thereafter, we examined whether the patient had systemic LCH lesions in the lungs, bones, and other organs. None was found except for abnormal brain MRI findings showing a thickened pituitary stalk and absent high signal at the posterior lobe of pituitary on TIWI (figure not shown). Based on her symptoms of polyuria/polydipsia, she was diagnosed with LCH-related central diabetes insipidus. Serum levels of antidiuretic hormone were undetectable (<0.8; reference value: >4.2 pg/mL). The reason for the delayed diagnosis of central diabetes insipidus was because her physician had been so concerned about treating axillary ulcer and her occasional complaints of polyuria/polydipsia were thought to be due to diabetes mellitus. After the diagnosis of LCH, we chose to treat this patient systematically, because the axillary ulcer was so deep and enlarged (see Figure 1(a)) along with the presence of CNS lesion. The patient underwent treatment with DDAVP for central diabetes and systemic chemotherapy consisting of (I) vinblastine (VBL; 8 mg/day, intravenous infusion) and prednisolone (PSL; 30 mg/day, intravenous infusion) on Day 1 and (II) cytosine arabinoside (AraC; 200 mg/day, intravenous infusion) and PSL (30 mg/day, intravenous infusion) on Day 2 every 4 weeks. After 8 cycles of chemotherapy, the axillary ulcer healed and cutaneous lesions disappeared; however, the thickened pituitary stalk in the CNS was unchanged. Three months later, the axillary ulcer relapsed and cutaneous eruptions reappeared, and diagnosis of LCH was again confirmed by a biopsy (Figure 3). Central diabetes insipidus did not exacerbate and no increase of DDAVP dose was required. This time, considering the adverse effects of the previous systemic chemotherapy (glucose intolerance in the

Figure 1: Photos of pretreatment right-axillary ulcer (a); cutaneous eruptions of LCH at the retroauricular area (b), scalp (c), and under the breast (d); posttreatment (after 4.5 months of imiquimod) status at the right axilla (e).
presence of diabetes mellitus and progressive dementia), we chose to employ topical imiquimod to treat the relapsed axillary ulcer and cutaneous LCH lesions, in addition to continuation of DDAVP for central diabetes insipidus. In this case, imiquimod (5%) cream was applied 5 days a week to the right axilla, scalp, and retroauricular areas and lower chest lesions, according to the instructions of the manufacturer. Following treatment for 4 months, the relapsed axillary ulcer as well as other cutaneous lesions improved significantly (Figure 1(e)). During the total 6.5 months of imiquimod treatment, no adverse effects such as fever or cutaneous redness, sore, and exfoliation were noted. At the time of writing this paper, more than 8 months after stopping the imiquimod treatment, no further relapse of the axilla and other cutaneous lesions was noted. We assessed the therapeutic results as a clinical remission, since no biopsy was performed to confirm the complete loss of LCH cells, as summarized in Table 1.

3. Discussion

Imiquimod, a cytokine inducer and a modifier of the innate immune response [14], is approved in Japan for the treatment of genital warts and actinic keratosis. Imiquimod is believed to
<table>
<thead>
<tr>
<th>References</th>
<th>Case (age/gender)</th>
<th>Disease</th>
<th>Systemic chemotherapy</th>
<th>Previous Rx Topical Rx for skin LCH</th>
<th>Topical imiquimod; duration (response)</th>
<th>Follow-up/outcome after finishing imiquimod</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dodd and Hook [13]</td>
<td>16 mo/F</td>
<td>Isolated skin LCH alone</td>
<td>None</td>
<td>Corticosteroids/tacrolimus.</td>
<td>5 months (CR)</td>
<td>&gt;2 yrs No relapse</td>
</tr>
<tr>
<td>Aubert-Wastiaux et al. [12]</td>
<td>4 yr/M</td>
<td>Simultaneous skin LCH with T-ALL</td>
<td>For T-ALL</td>
<td>None</td>
<td>1 month (CHR)</td>
<td>Aggressive LCH Died in &lt;2 months</td>
</tr>
<tr>
<td>O’Kane et al. [11]</td>
<td>53 yr/F</td>
<td>Breast carcinoma, followed by isolated skin LCH</td>
<td>For breast carcinoma</td>
<td>None</td>
<td>6 weeks (CHR)</td>
<td>Relapse after 6 months and then repeat imiquimod CR for 12 months</td>
</tr>
<tr>
<td>Taverna et al. [10]</td>
<td>74 yr/F</td>
<td>Isolated skin LCH alone</td>
<td>None</td>
<td>Ketoconazole/hydrocortisone</td>
<td>2 months (CR)</td>
<td>Relapse after 6 months and then repeat imiquimod</td>
</tr>
<tr>
<td>Current</td>
<td>61 yr/F</td>
<td>Skin LCH/CDI</td>
<td>For LCH ulcer</td>
<td>None</td>
<td>6.5 months (CR)</td>
<td>&gt;8 months No relapse</td>
</tr>
</tbody>
</table>

LCH: Langerhans cell histiocytosis; ALL: acute lymphocytic leukemia; CDI: central diabetes insipidus; Rx: treatment; CR: clinical remission (not confirmed by biopsy after treatment); CHR: complete histological remission (confirmed by biopsy after treatment).
The authors declare that they have no conflicts of interest.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References
